FailSafe®: Engineered safety for tomorrow’s cell therapies
Chimeric antigen receptor (CAR) T-cell therapies are a novel class of targeted and personalized immunotherapy which have shown remarkable success to date in treating certain hematological malignancies, including certain types of leukemia and lymphoma. There are currently six commercially available CAR T-Cell therapies: Abecma, Breyanzi, Kymriah, Tecartus, Yescarta, and Carvykti (Ghosh, 2023). There are a …
FailSafe®: Engineered safety for tomorrow’s cell therapies Read More »